carthera.eu

Revisión web de carthera.eu

Home - Carthera

 Generado el 09 Abril 2026 01:59 AM

Resultados antiguos? ACTUALIZAR !

La puntuación es 61/100

Contenido SEO

Título

Home - Carthera

Longitud : 15

Perfecto, tu título contiene entre 10 y 70 caracteres.

Descripción

Revolutionizing severe brain disease treatments

Longitud : 47

Preferiblemente tu descripción meta debe contener entre 70 y 160 caracteres (espacios incluidos). Usa esta herramienta gratuita para calcular la longitu del texto.

Palabras Claves (Keywords)

Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.

Propiedades Meta Og

Bien. Tu página usa propiedades Og (etiquetas og).

Propiedad Contenido
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Titulos

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Imagenes

Hemos encontrado 102 imágenes en esta web.

71 atributos alt están vacios o no existen. Agrega texto alternativo para que los motores de búsqueda puedan entender las imágenes.

Ratio Texto/HTML

Ratio : 31%

Ideal! El ratio entre texto y código HTML de esta página está entre 25 y 70 por ciento.

Flash

Perfecto, no se ha detectado contenido Flash en la página.

Iframe

Muy mal, tienes Iframes en la página, esto significa que el contenido no podrá ser indexado.

Reescritura URL

Bien. Tus enlaces parecen amigables

Guiones bajos en las URLs

Perfecto! No hemos detectado guiones bajos en tus URLs

Enlaces en página

Hemos encontrado un total de 10 enlaces incluyendo 0 enlace(s) a ficheros

Ancla Tipo Jugo
About Us Interna Pasando Jugo
Our Solutions Interna Pasando Jugo
Research & Development Interna Pasando Jugo
Our News Interna Pasando Jugo
Legal Mentions & Disclaimer Interna Pasando Jugo
Privacy Policy Interna Pasando Jugo
U.S. Expanded Access Policy Interna Pasando Jugo
Sitemap Interna Pasando Jugo
Contact (EN) Interna Pasando Jugo
Kookline Externo Pasando Jugo

Palabras Clave SEO

Nube de Palabras Clave

more request glioblastoma carthera brain scientific read publication ultrasound barrier

Consistencia de las Palabras Clave

Palabra Clave (Keyword) Contenido Título Palabras Claves (Keywords) Descripción Titulos
publication 69
scientific 34
carthera 32
request 32
brain 32

Usabilidad

Url

Dominio : carthera.eu

Longitud : 11

Favicon

Genial, tu web tiene un favicon.

Imprimibilidad

No hemos encontrado una hoja de estilos CSS para impresión.

Idioma

Genial. Has declarado el idioma en.

Dublin Core

Esta página no usa Dublin Core.

Documento

Tipo de documento (Doctype)

HTML 5

Codificación

Perfecto. Has declarado como codificación UTF-8.

Validez W3C

Errores : 0

Avisos : 0

Privacidad de los Emails

Atención! Hemos encontrado por lo menos una dirección de correo electrónico en texto plano. Usa este protector antispam gratuito para ocultarla de los spammers.

HTML obsoleto

Genial, no hemos detectado ninguna etiqueta HTML obsoleta.

Consejos de Velocidad

Excelente, esta web no usa tablas.
Muy mal, tu web está usando estilos embenidos (inline CSS).
Genial, tu página web usa muy pocos ficheros CSS.
Perfecto, tu web usa pocos ficheros JavaScript.
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto!

Movil

Optimización Móvil

Icono para Apple
Etiqueta Meta Viewport
Contenido Flash

Optimización

Mapa del sitio XML

¡Perfecto! Su sitio tiene un mapa del sitio en XML.

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

¡Estupendo! Su sitio web tiene un archivo robots.txt.

Herramientas de Analítica

No disponible

No hemos encontrado ninguna herramienta de analítica en esta web.

La analítica Web le permite medir la actividad de los visitantes de su sitio web. Debería tener instalada al menos una herramienta de analítica y se recomienda instalar otra más para obtener una confirmación de los resultados.

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web